Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.

"Declarations Ethics approvalThe study was approved by the Research Ethics Committee of the Autonomous Community of Aragon (CEICA) and classify by the AEMPS as EPA-SP (ID: GEE-ELI 2017–01). Consent to participateInformed consent was obtained from all subjects involved in the study. All authors consent for publication and accepted the last version of the manuscript. Competing interestsLaura López de Frutos Ph.D. is an employee of Azafaros B.V. outside the submitted work without stock options. Competing interests Laura López de Frutos Ph.D. is an employee of Azafaros B.V. outside the submitted work without stock options."

"Funding TRAZELGA (GZ-2017-11713) received a grant from Sanofi for its realization. The work has been partially granted by a FEETEG Research Grant (ID#1703)."